Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dengue and chikungunya virus transmission in Kinshasa, Democratic Republic of the Congo.

medRxiv : the preprint server for health sciences·2026
Same author

Integrated Surveillance Strategies and Clinical Characteristics of Arboviral Diseases in a Pediatric Cohort in Merida, Mexico, 2021-2023.

The American journal of tropical medicine and hygiene·2026
Same author

Yellow Fever in Pregnancy: A Comprehensive Review of the Clinical Implications and Vaccination in the Context of the 2024-2026 Americas Outbreak.

Tropical medicine and infectious disease·2026
Same author

Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.

The New England journal of medicine·2026
Same author

Roles of children, isolation measures and socioeconomic status in SARS-CoV-2 household transmission: a retrospective cohort study in a southern US city.

BMJ public health·2026
Same author

Update on emerging and re-emerging vector-borne diseases.

The American journal of the medical sciences·2025

Related Experiment Video

Updated: Feb 25, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Progress and Works in Progress: Update on Flavivirus Vaccine Development.

Matthew H Collins1, Stefan W Metz2

  • 1Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina.

Clinical Therapeutics
|July 30, 2017
PubMed
Summary

Flaviviruses pose a global health threat, causing severe diseases like dengue and Zika. Developing effective vaccines is crucial for controlling these mosquito-borne viral infections and reducing their impact.

Keywords:
Zikadengueflavivirusimmunizationimmunologic memoryvaccine development

More Related Videos

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.7K

Related Experiment Videos

Last Updated: Feb 25, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.7K

Area of Science:

  • Virology
  • Public Health
  • Vaccinology

Background:

  • Flaviviruses are a significant global health concern, causing diverse and severe human diseases.
  • Mosquito-borne flaviviruses, such as dengue and Zika, have expanding geographic ranges and cause substantial morbidity and mortality.
  • Existing vaccines for some flaviviruses demonstrate the potential of vaccination, but challenges remain for others like Zika and dengue.

Purpose of the Study:

  • To highlight the global health burden posed by flaviviruses.
  • To discuss the challenges and promise of flavivirus vaccine development and delivery.
  • To emphasize the importance of vaccination as a public health strategy against flavivirus infections.

Main Methods:

  • Review of current flavivirus epidemiology and disease manifestations.
  • Analysis of existing flavivirus vaccines and their limitations.
  • Discussion of challenges in vaccine development and public health implementation.

Main Results:

  • Billions are at risk globally from various flavivirus infections.
  • Dengue virus infects approximately 400 million people annually; Zika virus has emerged explosively.
  • Vaccination is a key strategy, but development and delivery face numerous hurdles.

Conclusions:

  • Intensified investment in flavivirus vaccine research and development is essential.
  • Overcoming challenges in vaccine creation and distribution holds promise for reducing global disease burden.
  • Effective flavivirus vaccines are critical for public health interventions worldwide.